Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults.

Toma L, Buckley K, Early N

The Senior care pharmacist1 Apr 2026

PMID41966038 (opens in a new tab)DOI10.4140/tcp.n.2026.78 (opens in a new tab)PepBankPUB-41966038
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 69-year-old man with type 2 diabetes and obesity, weight fell within the first few weeks of semaglutide therapy.

    In plain wordsOne older man lost weight within the first few weeks of semaglutide. One case cannot show semaglutide caused it.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight reduction
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient experiences weight reduction within the first few weeks of therapy
  2. 02HumanCase report or seriesSafety outcome

    In a 69-year-old man with type 2 diabetes, semaglutide was reported as well tolerated.

    In plain wordsOne older man tolerated semaglutide well, according to the case report.

    Peptide
    Semaglutide
    Outcome
    No significant changeTolerability
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and tolerates treatment well.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.